TYLER, TX - Physicians at the ETMC Cardiovascular Institute are among the first in the U.S. to treat paroxysmal atrial fibrillation patients with the new Medtronic Arctic Front Advance ™ Cardiac Cryoballoon System and FlexCath Advance™ Steerable Sheath.
Building upon the proven safety and efficacy of the original system, Medtronic’s second-generation technology provides an efficient approach to treating this common, yet serious, heart rhythm condition that affects approximately three million Americans.
Tyler Cardiovascular Consultants, P.A. working with ETMC are the first to bring this technology to East Texas.
The Arctic Front Advance System is used in minimally invasive procedures to isolate the pulmonary veins using coolant. Delivered via a catheter, the cryoballoon technology is associated with faster procedure times than point-by-point radiofrequency ablation and better treatment outcomes than drug therapies on the market. Additionally, the Arctic Front Advance cryoballoon features the new EvenCool™ Cryo Technology, which optimizes the delivery of coolant inside the balloon; the larger, more uniform cold surface reduces the effort needed to isolate the pulmonary veins, and improves physicians’ ability to treat patients with complicated anatomies as compared to the original cryoballoon.
“This next-generation cryoballoon technology provides the same high-caliber, clinically validated features of its predecessor, while offering the benefits of greater treatment efficiency,” said Dr. Raul Torres with Tyler Cardiovascular Consultants. “By treating patients with the most advanced, clinically relevant technology, we are better equipped to successfully manage their atrial fibrillation, thereby improving their overall quality-of-life.”
The FlexCath Advance Steerable Sheath has a deflection of 135 degrees, compared to the 90 degree deflection rate of its first-generation predecessor. This greater degree of deflection may allow the cryoballoon to be better maneuvered and positioned within the heart to achieve maximum treatment benefit.
The Arctic Front Advance Cryoballoon System and its predecessor have been used to treat more than 50,000 patients in 32 countries.
Atrial fibrillation is the most common and one of the most undertreated heart rhythm disorders. It is estimated that half of all diagnosed atrial fibrillation patients fail drug therapy and if left untreated, patients have up to a five times higher risk of stroke and an increased chance of developing heart failure. Paroxysmal atrial fibrillation occurs when irregular heartbeats in the upper chambers start and stop suddenly on their own, usually for minutes or days at a time.